<?xml version='1.0' encoding='utf-8'?>
<collection xmlns:z="https://github.com/zbmed-semtec/whatizit-dictionary-ner/">
<document>
<id>
   18381570
  </id>
<passage>
<infon key="type">
    title
   </infon>
<offset>
    0
   </offset>
<text>
    BRAFV600E <z:mesh cui="C0026882" id="http://purl.bioontology.org/ontology/MESH/D009154" semantics="http://purl.bioontology.org/ontology/STY/T045">mutation</z:mesh> is associated with preferential <z:mesh cui="C0036668, C0037791, C0036667" id="http://purl.bioontology.org/ontology/MESH/D012680" semantics="http://purl.bioontology.org/ontology/STY/T081">sensitivity</z:mesh> to <z:mesh cui="C0169101, C0752313" id="http://purl.bioontology.org/ontology/MESH/D020929" semantics="http://purl.bioontology.org/ontology/STY/T126, http://purl.bioontology.org/ontology/STY/T116">mitogen-activated protein kinase kinase</z:mesh> inhibition in <z:mesh cui="C0040136, C0549473, C0151468" id="http://purl.bioontology.org/ontology/MESH/D013964" semantics="http://purl.bioontology.org/ontology/STY/T191">thyroid cancer</z:mesh> <z:mesh cui="C0007600" id="http://purl.bioontology.org/ontology/MESH/D002460" semantics="http://purl.bioontology.org/ontology/STY/T025">cell lines</z:mesh>.
   </text>
</passage>
<passage>
<infon key="type">
    abstract
   </infon>
<offset>
    147
   </offset>
<text>
    CONTEXT: Mutually exclusive <z:mesh cui="C0026882" id="http://purl.bioontology.org/ontology/MESH/D009154" semantics="http://purl.bioontology.org/ontology/STY/T045">mutations</z:mesh> of RET, RAS, or BRAF are present in about 70% of <z:mesh cui="C0238463, C3501844, C3501843" id="http://purl.bioontology.org/ontology/MESH/D000077273" semantics="http://purl.bioontology.org/ontology/STY/T191">papillary thyroid carcinomas</z:mesh>, whereas only the latter two are seen in poorly differentiated and anaplastic <z:mesh cui="C0086692, C0006826, C0027651" id="http://purl.bioontology.org/ontology/MESH/D009369" semantics="http://purl.bioontology.org/ontology/STY/T191">cancers</z:mesh>. Although the signal output common to these <z:mesh cui="C0029005" id="http://purl.bioontology.org/ontology/MESH/D015513" semantics="http://purl.bioontology.org/ontology/STY/T123, http://purl.bioontology.org/ontology/STY/T116">oncoproteins</z:mesh> is ERK, a recent <z:mesh cui="C0242480, C2936319, C0242482, C0242585, C0242586, C0684224" id="http://purl.bioontology.org/ontology/MESH/D058028" semantics="http://purl.bioontology.org/ontology/STY/T170, http://purl.bioontology.org/ontology/STY/T062">report</z:mesh> showed that only BRAF <z:mesh cui="C0026882" id="http://purl.bioontology.org/ontology/MESH/D009154" semantics="http://purl.bioontology.org/ontology/STY/T045">mutations</z:mesh> consistently predicted responsiveness to <z:mesh cui="C0169101, C0752313" id="http://purl.bioontology.org/ontology/MESH/D020929" semantics="http://purl.bioontology.org/ontology/STY/T126, http://purl.bioontology.org/ontology/STY/T116">MAPK kinase</z:mesh> (<z:mesh cui="C0169101, C0752313" id="http://purl.bioontology.org/ontology/MESH/D020929" semantics="http://purl.bioontology.org/ontology/STY/T126, http://purl.bioontology.org/ontology/STY/T116">MEK</z:mesh>) <z:mesh cui="C0243076, C0003139, C0243077" id="http://purl.bioontology.org/ontology/MESH/Q000037" semantics="http://purl.bioontology.org/ontology/STY/T120">inhibitors</z:mesh>. OBJECTIVES: Here we investigated whether <z:mesh cui="C0036668, C0037791, C0036667" id="http://purl.bioontology.org/ontology/MESH/D012680" semantics="http://purl.bioontology.org/ontology/STY/T081">sensitivity</z:mesh> to <z:mesh cui="C0169101, C0752313" id="http://purl.bioontology.org/ontology/MESH/D020929" semantics="http://purl.bioontology.org/ontology/STY/T126, http://purl.bioontology.org/ontology/STY/T116">MEK</z:mesh> inhibition was determined by <z:mesh cui="C0029016" id="http://purl.bioontology.org/ontology/MESH/D009857" semantics="http://purl.bioontology.org/ontology/STY/T028">oncogene</z:mesh> status in 13 <z:mesh cui="C0086418" id="http://purl.bioontology.org/ontology/MESH/D006801" semantics="http://purl.bioontology.org/ontology/STY/T016">human</z:mesh> <z:mesh cui="C0040136, C0549473, C0151468" id="http://purl.bioontology.org/ontology/MESH/D013964" semantics="http://purl.bioontology.org/ontology/STY/T191">thyroid cancer</z:mesh> <z:mesh cui="C0007600" id="http://purl.bioontology.org/ontology/MESH/D002460" semantics="http://purl.bioontology.org/ontology/STY/T025">cell lines</z:mesh>: four with BRAF <z:mesh cui="C0026882" id="http://purl.bioontology.org/ontology/MESH/D009154" semantics="http://purl.bioontology.org/ontology/STY/T045">mutations</z:mesh>, four RAS, one RET/PTC1, and four wild type. RESULTS: <z:mesh cui="C0243107, C1135598, C1457898, C0220844, C0243109" id="http://purl.bioontology.org/ontology/MESH/Q000254" semantics="http://purl.bioontology.org/ontology/STY/T169, http://purl.bioontology.org/ontology/STY/T040, http://purl.bioontology.org/ontology/STY/T039, http://purl.bioontology.org/ontology/STY/T033">Growth</z:mesh> of BRAF (+) <z:mesh cui="C0007634" id="http://purl.bioontology.org/ontology/MESH/D002477" semantics="http://purl.bioontology.org/ontology/STY/T025">cells</z:mesh> was inhibited by the <z:mesh cui="C0169101, C0752313" id="http://purl.bioontology.org/ontology/MESH/D020929" semantics="http://purl.bioontology.org/ontology/STY/T126, http://purl.bioontology.org/ontology/STY/T116">MEK</z:mesh> antagonist <z:mesh cui="C1675748" id="http://purl.bioontology.org/ontology/MESH/C506614" semantics="http://purl.bioontology.org/ontology/STY/T109, http://purl.bioontology.org/ontology/STY/T121">PD0325901</z:mesh> with an IC(50) of less than 5 nm. By contrast, RAS, RET/PTC1, or wild-type <z:mesh cui="C0007634" id="http://purl.bioontology.org/ontology/MESH/D002477" semantics="http://purl.bioontology.org/ontology/STY/T025">cells</z:mesh> had IC(50) of 4 nm to greater than 1000 nm. <z:mesh cui="C0036668, C0037791, C0036667" id="http://purl.bioontology.org/ontology/MESH/D012680" semantics="http://purl.bioontology.org/ontology/STY/T081">Sensitivity</z:mesh> was not predicted by coexisting <z:mesh cui="C0026882" id="http://purl.bioontology.org/ontology/MESH/D009154" semantics="http://purl.bioontology.org/ontology/STY/T045">mutations</z:mesh> in PIK3CA or by PTEN status. Similar effects were obtained with the <z:mesh cui="C0169101, C0752313" id="http://purl.bioontology.org/ontology/MESH/D020929" semantics="http://purl.bioontology.org/ontology/STY/T126, http://purl.bioontology.org/ontology/STY/T116">MEK</z:mesh> inhibitor <z:mesh cui="C1832054, C2980074, C1541456" id="http://purl.bioontology.org/ontology/MESH/C517975" semantics="http://purl.bioontology.org/ontology/STY/T109, http://purl.bioontology.org/ontology/STY/T121">AZD6244</z:mesh>. <z:mesh cui="C1675748" id="http://purl.bioontology.org/ontology/MESH/C506614" semantics="http://purl.bioontology.org/ontology/STY/T109, http://purl.bioontology.org/ontology/STY/T121">PD0325901</z:mesh> induced a sustained G1/S arrest in BRAF (+) but not BRAF (-) lines. <z:mesh cui="C1675748" id="http://purl.bioontology.org/ontology/MESH/C506614" semantics="http://purl.bioontology.org/ontology/STY/T109, http://purl.bioontology.org/ontology/STY/T121">PD0325901</z:mesh> was equipotent at inhibiting pERK1/2 after 2 h, regardless of <z:mesh cui="C4042916" id="http://purl.bioontology.org/ontology/MESH/D000068617" semantics="http://purl.bioontology.org/ontology/STY/T032">genetic background</z:mesh>, but pERK rebounded at 24 h in most lines. <z:mesh cui="C0169101, C0752313" id="http://purl.bioontology.org/ontology/MESH/D020929" semantics="http://purl.bioontology.org/ontology/STY/T126, http://purl.bioontology.org/ontology/STY/T116">MEK</z:mesh> inhibitor resistance was associated with partial refractoriness of pERK to further inhibition by the compounds. <z:mesh cui="C1832054, C2980074, C1541456" id="http://purl.bioontology.org/ontology/MESH/C517975" semantics="http://purl.bioontology.org/ontology/STY/T109, http://purl.bioontology.org/ontology/STY/T121">AZD6244</z:mesh> was more potent at inhibiting <z:mesh cui="C0243107, C1135598, C1457898, C0220844, C0243109" id="http://purl.bioontology.org/ontology/MESH/Q000254" semantics="http://purl.bioontology.org/ontology/STY/T169, http://purl.bioontology.org/ontology/STY/T040, http://purl.bioontology.org/ontology/STY/T039, http://purl.bioontology.org/ontology/STY/T033">growth</z:mesh> of NPA (BRAF +) than Cal62 (KRAS +) <z:mesh cui="C0522537" id="http://purl.bioontology.org/ontology/MESH/D064593" semantics="http://purl.bioontology.org/ontology/STY/T122">xenografts</z:mesh>. CONCLUSION: <z:mesh cui="C0040136, C0549473, C0151468" id="http://purl.bioontology.org/ontology/MESH/D013964" semantics="http://purl.bioontology.org/ontology/STY/T191">Thyroid cancers</z:mesh> with BRAF <z:mesh cui="C0026882" id="http://purl.bioontology.org/ontology/MESH/D009154" semantics="http://purl.bioontology.org/ontology/STY/T045">mutation</z:mesh> are preferentially sensitive to <z:mesh cui="C0169101, C0752313" id="http://purl.bioontology.org/ontology/MESH/D020929" semantics="http://purl.bioontology.org/ontology/STY/T126, http://purl.bioontology.org/ontology/STY/T116">MEK</z:mesh> <z:mesh cui="C0243076, C0003139, C0243077" id="http://purl.bioontology.org/ontology/MESH/Q000037" semantics="http://purl.bioontology.org/ontology/STY/T120">inhibitors</z:mesh>, whereas <z:mesh cui="C0086692, C0006826, C0027651" id="http://purl.bioontology.org/ontology/MESH/D009369" semantics="http://purl.bioontology.org/ontology/STY/T191">tumors</z:mesh> with other <z:mesh cui="C0169101, C0752313" id="http://purl.bioontology.org/ontology/MESH/D020929" semantics="http://purl.bioontology.org/ontology/STY/T126, http://purl.bioontology.org/ontology/STY/T116">MEK</z:mesh>-ERK effector pathway <z:mesh cui="C0017337, C0440471, C0008844" id="http://purl.bioontology.org/ontology/MESH/D005796" semantics="http://purl.bioontology.org/ontology/STY/T028">gene</z:mesh> <z:mesh cui="C0026882" id="http://purl.bioontology.org/ontology/MESH/D009154" semantics="http://purl.bioontology.org/ontology/STY/T045">mutations</z:mesh> have variable responses, either because they are only partially dependent on ERK and/or because <z:mesh cui="C0015744" id="http://purl.bioontology.org/ontology/MESH/D005246" semantics="http://purl.bioontology.org/ontology/STY/T067">feedback</z:mesh> responses elicit partial refractoriness to <z:mesh cui="C0169101, C0752313" id="http://purl.bioontology.org/ontology/MESH/D020929" semantics="http://purl.bioontology.org/ontology/STY/T126, http://purl.bioontology.org/ontology/STY/T116">MEK</z:mesh> inhibition.
   </text>
</passage>
</document>
</collection>